Mode
Text Size
Log in / Sign up
Phase 2 N=36 Randomized Double-blind Treatment

Improving Therapeutic Learning in Depression: Proof of Concept

Major Depressive Disorder

Enrolled (actual)
36
Serious AEs
0.0%
Results posted
Sep 2018
Primary outcome: Primary: Recall of Cognitive Therapy Content — 25.4; 26.8; 24.7; 28.2 Number of correct units of information

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
250 mg DCS (Drug); 100 mg Modafinil (Drug); Placebo (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Boston University Charles River Campus
Primary completion
Apr 2017

Outcome Measures

OutcomeResultp-value
PRIMARY
Recall of Cognitive Therapy Content
25.4; 26.8; 24.7; 28.2; 29.7; 28.7
PRIMARY
1 Week Delayed Recall of Emotional Story Items
13.5; 21.3; 16.1; 25.0; 37.3; 26.4
PRIMARY
1 Week Delayed Recall Logical Memory
1.8; 4.4; 5.0; 9.5; 12.8; 13.6
SECONDARY
Logical Memory Immediate Recall
14.8; 17.1; 16.2; 17.7; 17.8; 18.2
SECONDARY
Immediate Memory Measured by the Hopkins Verbal Learning Task
8.5; 9.6; 9.6; 7.8; 9.9; 9.4
SECONDARY
Immediate Recall of Emotional Story Items
22.4; 35.2; 32.2; 34.4; 46.8; 35.5
SECONDARY
Skills of Cognitive Therapy
23.3; 20.5; 24.8; 26.4; 24.3; 25.7
SECONDARY
Digits Backward
8.3; 9.5; 11.3; 9.25; 10.4; 12.2

Summary

Despite advances in both pharmacotherapy and psychotherapy for major depression, non-response and partial-response remain relatively common outcomes, motivating the search for new treatments. This study is concerned with the development of one such novel treatment, the augmentation of exposure-based cognitive-behavior therapy (CBT) with d-cycloserine (DCS).

Eligibility Criteria

Inclusion Criteria

  • Must have a DSM diagnosis of major depression as determined by structured diagnostic interview
  • Must be free of psychotropic medications other than serotonin selective reuptake inhibitors (SSRIs) for at least 2 weeks
  • No current suicidal ideation
  • Able to speak and understand English
  • Must be between the ages of 18 and 65, inclusive
  • Must be a male, or a female who is not of childbearing potential (i.e., surgically sterile, postmenopausal for at least 1 year) or who is non-pregnant, non-lactating and using a medically accepted method of contraception. Acceptable methods of contraception include condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicide, medically prescribed IUD, hormonal contraceptives. A woman of childbearing potential who is not currently sexually active must agree to use a medically accepted method of contraception should she become sexually active while participating in the trial

Exclusion Criteria

  • A DSM diagnosis of dementia, neurodegenerative disease, or other organic mental disorder; substance use disorder other than nicotine or caffeine in the last 3 months; bulimia or anorexia within the last 3 months; lifetime history of psychotic disorder or, bipolar disorder, or developmental disorder;
  • A diagnosis of organic brain syndrome, mental retardation, or other cognitive dysfunction that could interfere with a participants capacity to participate in CBT or to complete safety and efficacy assessments
  • A history of seizures (apart from childhood febrile seizures) or head trauma causing ongoing cognitive impairment
  • An uncontrolled, unstable clinically significant medical condition (e.g., renal, endocrine, hepatic, respiratory, cardiovascular, hematologic, immunologic or cerebrovascular disease, or malignancy, or poorly controlled hypertension (> 150/90mmHg) that may interfere with the interpretation of safety and efficacy evaluations in the opinion of the study physician or investigator
  • Medical illness including hypertension, cardiac disease, liver disease, pulmonary diseases, central nervous system disease, and epilepsy;
  • Recent (1 year) suicidal attempts or current suicidal ideation
  • For women, currently pregnant, plans to be pregnant in the next 2 months, or currently breastfeeding
  • Treatment with phenytoin, isoniazid, or propranolol or known sensitivity to modafinil or cycloserine
  • A history of head trauma causing loss of consciousness, seizure or ongoing cognitive impairment
  • Use of psychotropic medication (including stimulants) other than SSRIs
  • Current daily use of alcohol or regular binge alcohol use as determined on the medical screen
  • Insufficient command of the English language (i.e., cannot carry on a conversation with an interviewer in the English language or read associated text)
  • Receipt of CBT in the previous five years
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02376257). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search